UP!
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2023 | 2022-11-10 | Future report Set alerts | |
| Q2 2023 | 2022-08-08 | -0.21 | -0.21 |
| Q1 2023 | 2022-05-12 | -0.37 | -0.37 |
| Q4 2022 | 2022-03-31 | -0.38 | -0.38 |
| Q1 2022 | 2022-03-24 | 0.00 | 0.00 |
| Q4 2021 | 2022-03-17 | 0.00 | 0.00 |
| Q3 2021 | 2021-11-17 | 0.00 | 0.00 |
| Q2 2021 | 2021-08-05 | -0.21 | -0.21 |
| Q1 2021 | 2021-06-01 | -0.23 | -0.23 |
| Q4 2020 | 2021-03-17 | -0.20 | -0.20 |
| 2016-02-10 | Downgrade | WallachBeth Capital | Hold to Sell | |
| 2016-02-10 | Downgrade | Piper Jaffray | Overweight to Neutral | $4.00 to $0.75 |
| 2016-02-10 | Downgrade | Ladenburg Thalmann | Buy to Neutral | |
| 2016-02-10 | Downgrade | Piper Jaffray Cos. | Overweight to Neutral | $4.00 to $0.75 |
| 2016-02-08 | Lower Price Target | Piper Jaffray | Overweight | $8.00 to $4.00 |
| 2016-02-08 | Lower Price Target | S&P Equity Research | $0.48 to $0.39 | |
| 2016-01-05 | Reiterated Rating | Piper Jaffray | Overweight | $8.00 |
| 2015-12-10 | Reiterated Rating | Piper Jaffray | Buy | |
| 2015-11-09 | Downgrade | WallachBeth Capital | Buy to Hold | $4.50 to $1.60 |
| 2015-09-23 | Reiterated Rating | Piper Jaffray | Buy | $8.00 |
| 2015-08-14 | Reiterated Rating | Roth Capital | Buy | $4.50 |
| 2015-06-01 | Set Price Target | Roth Capital | Buy | $4.50 |
| 2015-06-01 | Reiterated Rating | Janney Montgomery Scott | Buy to Fair Value | $3.50 to $1.94 |
| 2015-05-10 | Reiterated Rating | HC Wainwright | Buy | $6.00 to $4.00 |
| 2015-03-23 | Set Price Target | Roth Capital | Buy | $4.50 |
| 2015-03-09 | Set Price Target | Piper Jaffray | $6.00 to $8.00 | |
| 2014-09-08 | Initiated Coverage | Piper Jaffray | Overweight | $6.00 |
| 2014-08-05 | Upgrade | WallachBeth | Hold to Buy | $4.50 |
| 2014-08-05 | Upgrade | WallachBeth Capital | Hold to Buy | $4.50 |
| 2014-05-22 | Initiated Coverage | Ladenburg Thalmann | Buy | $6.00 |
| 2014-03-19 | Initiated | WallachBeth | Hold | $4.50 |
| 2014-03-19 | Initiated Coverage | WallachBeth Capital | Hold | $4.50 |
| 2013-11-04 | Initiated Coverage | HC Wainwright | Buy | $4.00 |
| 2013-10-29 | Initiated Coverage | Janney Montgomery Scott | Buy | |
| 2013-10-07 | Reiterated Rating | Wells Fargo & Co. | Positive | |
| 2013-10-07 | Reiterated Rating | Wells Fargo | Positive |
| 2016-02-10 | Downgrade | WallachBeth Capital | Hold to Sell | |
| 2016-02-10 | Downgrade | Piper Jaffray | Overweight to Neutral | $4.00 to $0.75 |
| 2016-02-10 | Downgrade | Ladenburg Thalmann | Buy to Neutral | |
| 2016-02-10 | Downgrade | Piper Jaffray Cos. | Overweight to Neutral | $4.00 to $0.75 |
| 2016-02-08 | Lower Price Target | Piper Jaffray | Overweight | $8.00 to $4.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In CTIC 94 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| STATE STREET CORP | 13.74M |
| BVF INC/IL | 8.81M |
| BlackRock Inc. | 6.60M |
| Stonepine Capital Management, LLC | 5.67M |
| Vanguard Group, Inc | 4.79M |
| NEA Management Company, LLC | 3.69M |
| BlackRock Institutional Trust Company, N.A. | 3.46M |
| WELLINGTON MANAGEMENT CO LLP | 2.82M |
| Ghost Tree Capital, LLC | 2.00M |
| GEODE CAPITAL MANAGEMENT, LLC | 1.78M |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1.63M |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 1.58M |
| Nuveen Asset Management, LLC | 1.35M |
| Verition Fund Management LLC | 1.24M |
| JPMORGAN CHASE & CO | 1.14M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| ORBIMED ADVISORS LLC | 3.33% (5000000) | AGLE / AMBI / ANTH / ATHX / BOLD / BONE / CRVS / CTIC / ICPT / KALA / LOXO / MRTX / OTIC / RLYP / ROKA / SIEN / SUPN / SYBX / XLRN / |
| BIANCO JAMES A President and CEO | 1.19% (1780133) | CTIC / |
| BVF PARTNERS L P/IL | 0.86% (1295582) | ARQL / ARRY / CAPS / CCXI / CNCE / CTIC / INFI / LGND / NBIX / ONTY / PTN / RGDO / RGEN / RIGL / TRGT / XENE / |
| SINGER JACK W EVP, Global Medical Affairs | 0.66% (994057) | CTIC / |
| BIANCO LOUIS A EVP, Finance & Administration | 0.42% (622933) | CTIC / |
| BAUER JOHN H | 0.40% (599011) | CTIC / |
| Plunkett Matthew EVP, Corporate Development | 0.35% (526210) | CTIC / |
| GREGORIAN VARTAN | 0.31% (468937) | CTIC / |
| BENNER STEVEN E EVP, Chief Medical Officer | 0.24% (363371) | CTIC / |
| MUNDINGER MARY ONEIL | 0.24% (360019) | CTIC / |
| SEELEY BRUCE J. EVP, Chief Commercial Officer | 0.21% (310000) | CTIC / NSTG / |
| Tuckson Reed Vaughn | 0.06% (92424) | CTIC / LPNT / |
| Telling Fred | 0.05% (78874) | CTIC / OGEN / |
| LOVE RICHARD L | 0.05% (73718) | CTIC / PRXL / |
| NUDELMAN PHILLIP M PHD | 0.05% (73129) | CTIC / |
| Ignagni Karen | 0.04% (66192) | CTIC / |
| PERRY MATTHEW D See Explanation of Responses | 0.03% (43139) | CTIC / XOMA / |
| Metzger Michael A | 0.01% (20121) | CTIC / RGDO / RGDX / |
UM